Altamira Therapeutics Ltd. (CYTO)
Fuera de horario:
Altamira Therapeutics Ltd.
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
441 295 5950
https://altamiratherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 10
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Thomas Meyer Ph.D. | Founder, President, Chairman, CEO & MD | 569.82k | N/D | 1968 |
| Mr. Marcel Gremaud CPA | Chief Financial Officer | N/D | N/D | 1959 |
| Dr. Covadonga Paneda | Chief Operating Officer | N/D | N/D | 1974 |
| Dr. Samuel A. Wickline M.D. | Chief Scientific Adviser | N/D | N/D | 1953 |
Descripción
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Gestión corporativa
La calificación ISS Governance QuickScore de Altamira Therapeutics Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
